Incyte INCB 50465-204 A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

September 17, 2018
https://clinicaltrials.gov/ct2/show/NCT03144674
Cancer - Lymphoma
Principal Investigator: Nalini Janakiraman, MD
INCB050465, Marginal Zone, Lymphoma
Accepting Participants